Symbols

IFRX

InflaRx·NASDAQ

--(--)

Signals Analysis

Bullish signal 2

Bearish signal 3

Consensus Rating "Strong Buy"

Ample Liquidity

Negative Gross Margin

EPS Below Expectations

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About IFRX

Inflarx N.V.

A clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system

Industry

Pharmaceutical

Established Date

Listing Date

11/08/2017

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.inflarx.com

Security Type

Common stock

Office address

Winzerlaer Str. 2, 07745 Jena, Germany

Business

Introduction

InflaRx N.V., formerly known as Fireman B.V., was incorporated under the laws of the Netherlands in June 2017 and is the holding company of InflaRx GmbH. The change was made in accordance with the terms of the company's reorganization. InflaRx is a biopharmaceutical company that utilizes its proprietary technology to discover, develop and commercialize inhibitors of complement activator C5a and its receptor C5aR. The company is committed to efficiently and selectively modulating the C5a/C5aR axis to inhibit the inflammatory response associated with complement activation, and to develop drug candidates for C5a-mediated inflammation-related diseases.

Company Financials

EPS

IFRX has released its 2025 Q1 earnings. EPS was reported at -0.13, versus the expected -0.17, beating expectations. The chart below visualizes how IFRX has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

IFRX has released its 2025 Q4 earnings report, with revenue of -39.82K, reflecting a YoY change of -8994.82%, and net profit of -12.49M, showing a YoY change of -136.05%. The Sankey diagram below clearly presents IFRX's revenue sources and cost distribution.